Shelhigh: Seized Devices and the Cost of Breaking the Order

The Shelhigh consent decree was a June 22, 2007 federal court order concerning seized medical devices and their reconditioning. The seizure and reconditioning order, entered in the District of New Jersey, put the company’s goods under the Food and Drug Administration’s supervision.

For manufacturing and quality employees, seized inventory brings the work inside the plant into focus. Purchasing specifications, production acceptance, nonconforming product, corrective action and storage all leave records of how a device reached the point of release.

Seized Inventory and the Factory Behind It

The government filed a complaint for forfeiture against devices in Shelhigh’s possession on April 16, 2007, and the United States Marshal seized them the next day under a court warrant. The June 22 consent order condemned the seized articles and forfeited them to the United States. Shelhigh could try to bring them into compliance only under a reconditioning plan the Food and Drug Administration accepted in writing. Anything not brought into compliance was to be destroyed at Shelhigh’s expense under an agency representative’s supervision, and the order recorded that the agency gave no assurance reconditioning would succeed.

The order also barred the company from manufacturing, processing, packing, labeling or distributing any seized device or component, or any device it received or processed after the seizure, until its methods, facilities and controls met the quality system regulation, the medical device reporting requirements and the order itself. For a manufacturing insider, the practical issue is the link between the condition of those goods and the decisions behind their release.

As general industry context, in the implant business, a hospital or ambulatory surgery center buys the device, while the surgeon may strongly influence which brand and type it purchases. The HHS Office of Inspector General described that division in its alert on physician-owned entities. The institution ordinarily receives a bundled Medicare payment for the procedure, with the implant included.

Hospitals buy the product, but patients live with it. Quality and regulatory employees can explain the production decisions behind goods that purchasing staff and clinicians encounter farther along that chain.

FDA Supervision Reaches the Factory

Device consent decrees often make restarting production depend on an independent expert’s work and the Food and Drug Administration’s written permission. The recurring arrangement puts the cost of that expert on the manufacturer and gives the agency control over when the restricted operation can resume. That is the wider enforcement setting for Shelhigh’s seizure and reconditioning order.

An insider who knows the work behind a corrective-action report can explain whether the report describes what actually happened in the plant. The important difference is between a correction on paper and a correction in production.

A later example shows how far that supervision can reach. The April 2024 Philips Respironics decree gave the Food and Drug Administration authority to order the company to stop manufacturing, holding, distributing, storing or servicing covered devices if the agency determined that the company had violated the law or the decree.

For manufacturing and distribution staff, that kind of restriction reaches the decisions they make every day: whether production runs, whether inventory stays in storage, and whether an order ships. The court order gave the agency continuing control over operations after the agreement was signed.

The Cost of Breaking Shelhigh’s Order

Shelhigh’s decree specified $4,000 per day plus $4,000 per violation for breaking the order. The daily provision made the duration of noncompliance matter. The separate charge for each violation also made the individual decisions matter.

For an insider whose work involved restricted goods, we examine the release decisions alongside the quality records and the company’s account of what it corrected.

What Complaint Files Tell the Manufacturer

The device manufacturer receives reports from outside its own plant as well as findings from its production staff. Hospitals send device-related serious-injury reports to the manufacturer when the manufacturer is known.

The manufacturer also assesses whether a malfunction would be likely to cause or contribute to death or serious injury if it happened again. That puts the company in the position of evaluating problems with its own product. Event investigations, testing and complaint trends can inform that decision.

The reporting rules reach information the company can obtain by testing or evaluating the device, and require investigation of each event and evaluation of its cause. For an insider, the useful connection is between what the company learned, how it evaluated the problem, and what it communicated outside the business.

Production records describe the work before release. Complaint records can show what the company learned afterward. We work with quality employees who know how those accounts fit together, including when a company’s explanation of a problem differs from the work they saw.

Production Changes That Mattered in Court

Utah Medical Products won when the government sought a court order restricting its operations. In its October 2005 decision, the court found that the company’s current production processes and procedures complied with the applicable requirements.

That comparison gives corrective-action records a concrete purpose: they can show what changed in production and when. Shelhigh resolved its proceeding through a consent order. Utah Medical Products contested the requested restrictions and defeated them.

Connecting Device Records to Government Payments

For an implant included in a hospital’s procedure payment, understanding what the government paid means understanding the institutional claim as well as the manufacturer’s records. Product knowledge and billing knowledge may sit with different people.

A 2020 Journal of Forensic and Investigative Accounting paper explains how inaccurate descriptions of goods or services can enter reimbursement requests, and how false statements about compliance can affect the government’s payment decision. Its analysis focuses attention on what the government was told about the goods or services it paid for.

We work with device insiders to understand that connection: what the product records show, who knew about the problem, and how it reached the purchasing and payment decisions. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know the Decisions Behind Restricted Devices

If you know how seized or restricted devices were handled inside a manufacturer, speak to one of our Whistleblower Experts about the release decisions you saw. We build your strongest medical device whistleblower case with you and bring in medical-device whistleblower lawyers who understand manufacturing records and government payment. We stay beside you as your knowledge of the product becomes the foundation of the case.